Description
Created On: 2020-07-15
Record Count: 20
Primary Industries
- Drugs
- Antibody
- Cancer
- Disease
- Drug Discovery
- Therapeutic
- Diagnostic
- Proteins
- Immune
- Genome
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 257239
Licensor grants an exclusive, worldwide, perpetual, irrevocable, non-terminable, license, with the right to grant and authorize the grant of sublicenses, under the Licensor Licensed Patents to Exploit any BiTE Products and BiTE Research Products.
This additional amendment added patent 5,223,409, entitled Directed evolution of novel binding proteins.
BiTE Product means any composition or formulation consisting of, containing or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells for the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions, but excluding any BiTE Research Product.
Diagnostic SCA (Single Chain Antibodies) Product means an SCA Product that is under development, approved or used for the diagnosis of human diseases or conditions.
Licensee Pipeline Product means any Licensed Product, other than a BiTE Product or BiTE Research Product, as to which Licensee obtains or retains Commercialization Rights, whether exclusive or co-exclusive, in one or more Major Market Countries, or Licensee or any of its Affiliates has filed or will file an IND in its own name.
Industrial SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies intended for any use other than for research or the diagnosis, prophylaxis, or treatment of disease or conditions in humans and other animals.
Licensor Pipeline Product means any Licensed Product as to which Licensor obtains or retains Commercialization Rights, whether exclusive or co-exclusive, in one or more Major Market Countries, or Licensor or its Affiliates has filed or will file an IND in its own name.
Non-Human SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies under development, approved or used for the diagnosis, prophylaxis or treatment of non-human diseases or conditions, but excluding any BiTE Products.
Research Product means a product consisting of, containing or comprising one or more Single Chain Antibodies used for research purposes and not intended, under development or used for the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions, but excluding any BiTE Research Product.
SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies that is under development, approved or used for the diagnosis, prophylaxis or treatment of human diseases or conditions, but excluding any BiTE Product.
Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and,
Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis Factor alpha (TNF-a) or Lymphotoxin, and, Single Chain Antibodies that bind to OP-1 or related proteins.
IPSCIO Record ID: 256277
BiTE Product means any composition or formulation consisting of, containing or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells for the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions, but excluding any BiTE Research Product.
Diagnostic SCA (Single Chain Antibodies) Product means an SCA Product that is under development, approved or used for the diagnosis of human diseases or conditions.
Licensee Pipeline Product means any Licensed Product, other than a BiTE Product or BiTE Research Product, as to which Licensee obtains or retains Commercialization Rights, whether exclusive or co-exclusive, in one or more Major Market Countries, or Licensee or any of its Affiliates has filed or will file an IND in its own name.
Industrial SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies intended for any use other than for research or the diagnosis, prophylaxis, or treatment of disease or conditions in humans and other animals.
Licensor Pipeline Product means any Licensed Product as to which Licensor obtains or retains Commercialization Rights, whether exclusive or co-exclusive, in one or more Major Market Countries, or Licensor or its Affiliates has filed or will file an IND in its own name.
Non-Human SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies under development, approved or used for the diagnosis, prophylaxis or treatment of non-human diseases or conditions, but excluding any BiTE Products.
Research Product means a product consisting of, containing or comprising one or more Single Chain Antibodies used for research purposes and not intended, under development or used for the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions, but excluding any BiTE Research Product.
SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies that is under development, approved or used for the diagnosis, prophylaxis or treatment of human diseases or conditions, but excluding any BiTE Product.
Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and,
Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis Factor alpha (TNF-a) or Lymphotoxin, and,
Single Chain Antibodies that bind to OP-1 or related proteins.
IPSCIO Record ID: 256278
Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.
Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.
GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.
Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.
The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.
Companies will collaboration to identify and develop antibody-based therapeutics for the treatment of inflammatory and autoimmune diseases.
IPSCIO Record ID: 256279
Licensor grants a worldwide, co-exclusive, with Licensor, right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology to make, have made, use, offer for sale, sell, and import any product that is not a BiTE Product for any use in humans.
BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.
Target means a cell-surface antigen. The list of proprietary targets is: epha2, alpha – V, and, beta-3.
BiTE(R) molecules are part of a novel class of antibody derivatives that may have the potential to selectively direct and activate the human immune system to act against cancer cells. This action is believed to occur as a result of the molecule's stimulation of T cells to target and destroy cancer cells that express a specific antigen.
BiTE molecule targeting CD19 is for the potential treatment of certain lymphomas.
IPSCIO Record ID: 256275
For the research license, the Licensor of England grants to the Licensee of Germany a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to perform research and development activities in the Licensee Research Field.
For the commercialization license, Licensor grants a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Licensee Licensed Field.
The know-how includes a Training Manual Antibody Phage Display 2002, and, Licensor mammalian expression lgG vectors.
Licensed Product means the MT201 Product and any other product, substance or formulation arising from the EpCAM Target Program, in each case, the Development, manufacture, importation, use or sale of which would, but for the provisions of this Agreement, infringe one or more Valid Claims under the Licensor Licensed Patents, or utilizes the Licensor Background Know-How.
Licensees Research Field means the identification or development of Antibody Products for the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the EpCAM Target.
The excluded field is the discovery, isolation, characterization, research, development, and/pr commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific rationale or activity is neuronal and/or glial mechanisms of action of neuroprotection: neurodegenerative conditions, diabetic neuropathy, pain, spinal cord injury, multiple sclerosis, and, stroke as a disease of the cerebrovasculature.
IPSCIO Record ID: 257238
BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.
Target means a cell-surface antigen. The list of proprietary targets is: epha2, alpha – V, and, beta-3.
BiTE molecules are designed to direct the body’s cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.
Licensee's product candidates aim to efficiently redirect the patient’s immune response to tumor cells either through the use of specific recombinant antibodies for the eradication of cancer cells, as is the case with adecatumumab, or through BiTE molecules, which target cancer cells for elimination by the patient’s own T cells.
IPSCIO Record ID: 260433
The German Licensor grants to the German Licensee an exclusive license, with the right to grant sublicenses, to the Licensed Technology, other than the Sublicensed Patents and the Sublicensed Know-How, to conduct research and development, make, have made, use, Commercialize, and import the Products in the Field in the Territory.
Licensor grants an exclusive sublicense, with the right to grant further sublicenses, under the rights and licenses granted to Licensor in the Upstream Agreements with respect to the Sublicensed Technology, to research, develop, Commercialize, make, have made, use, offer for sale, sell, and import the Products in the Field in the Territory.
This agreement includes a non-exclusive grant beck from Licensee to Licensor.
GM-CSF means the whole or part and natural variants of the granulocytemacrophage colony stimulating factor (GM-CSF) identified by the SWlSS-PROT entry name CSF2 _ HUMAN and accession number P04141 with the amino acid sequence as defined.
MT203 Product means any pharmaceutical product comprising the IgG1 antibody with the variable domain amino sequence.
The patents are for Antibody neutralizers of human granulocyte macrophage colony stimulating factor; and, Method of identifying binding site domains that retain the capacity of binding to an epitope.
IPSCIO Record ID: 280819
For the Commercial License, Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.
The two companies will collaborate on the development of human antibodies for the treatment of cancer.
IPSCIO Record ID: 256280
The German Licensor grants an exclusive, even as to Licensor, right and license under the Licensed Technology, to make, have made, use, offer for sale, sell, and import Licensed Product in the Territory.
For the option for Exclusive License to 998 Patent, Licensor grants an exclusive option to obtain an exclusive right and license under the 998 Patent, to make, have made, use, offer for sale, sell, and import Licensed Products in the United States of America for any use in humans.
The BiTE Product means any composition or formulation containing a BiTE Molecule.
IPSCIO Record ID: 256276
Licensed Product means any product, substance or formulation arising from the Target Program, and the Development, manufacture, importation, use or sale of which would but for the provisions of this Agreement infringe one or more Valid Claims under the Licensor Licensed Patents, or which utilizes the Licensor Background Know-How.
The know-how includes Training Manual Antibody Phage Display 2002, and, mammalian expression IgG vectors.
Licensee obtains the right within the framework of their collaboration to use Licensor’s intellectual property in phage display to create and commercialise novel antibody products against a defined number of targets.
IPSCIO Record ID: 243460
(a) Make or have made Licensed Antibody Phage Display Materials;
(b) Solely for Research and Development purposes, conduct Antibody Phage Display;
(c) Make or have made Research Quantities of a Licensed Immunoglobulin;
(d) Transfer Antibody Phage Display Materials, Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Licensee Collaborator; and
( e) Use, sell, offer to sell, import and export Licensed Immunoglobulins.
Antibody Phage Display means the authorized use of Licensed Antibody Phage Display Materials to conduct Research and Development.
Licensed Antibody Phage Display Materials means any collection or library of polynucleotide sequences, including without limitation a Licensee Library, created by Licensee and under the exclusive control of Licensee, which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage, including without limitation a Licensee Library, created by or under the exclusive control of Licensee, wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin and an outer surface polypeptide of a bacteriophage.
Licensed Immunoglobulin means any Immunoglobulin discovered, isolated or characterized by Licensee or a Licensee Collaborator through the use of Licensed Antibody Phage Display Materials.
IPSCIO Record ID: 257189
Licensor grants the German Licensee an exclusive, even as to Licensor, but not as to sublicensees of Licensee that receive a direct license from Licensor upon Licensees request, right and license, without the right to grant sublicenses, under Independent Licensor Technology, Licensors rights and interest in the Joint Collaboration Technology, and the Licensor Collaboration Technology to use such Commercial Process to make and have made the applicable Licensed Product for sale and use outside of the Territory.
With this agreement, Licensor is to develop a commercial scale manufacturing process for Licensed Products developed under this Agreement.
For the supply of licensed product Licensor will supply Licensee with Licensees requirements of such Clinical Trial Materials.
The BiTE Product means any composition or formulation containing a BiTE Molecule.
The field of use for this agreement is for any use in humans. MT103 is being evaluated for the treatment of patients with non-Hodgkins lymphoma.
IPSCIO Record ID: 202855
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
IPSCIO Record ID: 260370
The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.
— High Affinity Human Antibodies to Novel Tumor Antigens;
— Bi-specific Single Chain Fv scFv Antibody Molecule; and,
— Human Erb-B Antibodies.
IPSCIO Record ID: 121012
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
IPSCIO Record ID: 237232
The Licensor Know-how includes Licensor Training Manual Antibody Phage Display 2002, and, Licensor mammalian expression IgG vectors:
pEUl.2 (human gamma-I heavy chain)
pEU3.2 (human kappa light chain)
pEU4.2 (human lambda light chain)
pEU8.2 (human gamma-4 heavy chain)
Diagnostic Antibody Product means any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction or disease management of a disorder for any indication outside the Excluded Field which contains, comprises or the process of development or manufacture of which utilizes a Licensor Licensable Antibody. The term Diagnostic Antibody Product shall not include any Research Product.
Therapeutic Antibody Product means any preparation for the treatment or prevention of disease, infection or other condition in humans for any indication outside the Excluded Field which contains, comprises, or the process of development or manufacture of which utilizes, a Licensor Licensable Antibody. The term Therapeutic Antibody Product shall not include any Research Product.
Excluded Field means the discovery, isolation, characterization, research, development, and/or commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific rationale or activity is neuronal and/or glial mechanisms of action or neuroprotection:
(a) neurodegenerative conditions, including but not limited to (i) Alzheimers disease, and (ii) Parkinsons disease, but in both instances, excluding the treatment and/or prevention of neurodegenerative conditions in humans associated with P-amyloid deposition (including, without limitation, Alzheimers disease and/or Mild Cognitive Impairment, using either (A) immunological approaches directed at one or more epitopes of AP or any naturally occurring variants thereof, including, without limitation, the administration of an Antibody, or (B) use of a beta secretase inhibitor, including, without limitation, the administration of an Antibody);
(b) diabetic neuropathy;
(c) pain, including, but not limited to, (i) post-operative pain, (ii) chronic pain and (iii) neuropathic pain,
(d) spinal cord injury;
(e) multiple sclerosis; and/or
(f) stroke, as a disease of the cerebrovasculature.
The term Excluded Field shall not include the diagnosis, treatment and/or prevention of the above disease conditions caused by infectious pathogenic micro-organisms.
IPSCIO Record ID: 222550
For the Evaluation License, Licensor grants an exclusive, nontransferable license for the term of the applicable Evaluation Period to use the Collaboration Technology relating to such Antigen solely for the purpose of evaluating whether Licensee shall desire to acquire a commercial license to such Product(s) directed against such Antigen.
For the Option for Commercial Licenses, Licensee shall have an option to obtain a commercial license with respect to Product(s) directed against such Antigen in the Field of Use in all countries of the Territory,
For the Commercial License, Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensed Technology to make, have made, import, have imported, use, offer for sale and sell Product(s) directed against such Antigen in the Field of Use in the Territory.
For the Research License, Licensee shall have an irrevocable, perpetual, worldwide exclusive research license, without the right to sublicense, to make and use (but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Antibody{ies) and Antibody Cell(s) transferred by Licensor to Licensee, and any related Collaboration Technology, including Genetic Material(s) relating specifically and solely to such Antibody(ies) and Antibody Cell(s), in each case, and an irrevocable, perpetual, worldwide non-exclusive research license, without the right to sublicense, to make and use, but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Collaboration Technology relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, in each case, which is necessary for Licensee to make and use the same for research.
The Collaboration Know How shall mean, with respect to each Antigen, any parts or derivatives of the Mice prepared by Licensor in connection with the applicable Immunization and delivered to Licensee, including without limitation, Antibody(ies), Antibody Cell(s), polypeptides, Genetic Material(s) or other biological materials derived directly or indirectly from the Mice delivered to Licensee, all information relating specifically and solely to the foregoing, including without limitation, technical data, protocols and methods and processes with respect to Product(s) directed against such Antigen and, all information relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, including without limitation, technical data, protocols and methods and processes.
Product(s) shall mean, with respect to an Antigen, a composition or compositions with each composition comprising one or more Antibody(ies), Antibody Cell(s) or Genetic Material(s).
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.
HuMAb -Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.
Bispecific antibodies, which enhance and direct the body's own immune system to fight disease; and immunotoxin technology.
IPSCIO Record ID: 144995
The Diagnostic Product shall mean a diagnostic product, containing one or more Program Antibodies, for use in the in vivo detection of solid tumors in humans.
The Therapeutic Product shall mean the final dosage formulation of a product incorporating pharmaceutical compositions containing a Program Antibody for use in the treatment of solid tumors in humans, regardless of the route of administration. Each different chemical formulation of a Therapeutic Product containing the same one or more Program Antibodies but no additional antibodies, except different formulations for use in the treatment of the same indication in the Field by different routes of administration, shall constitute a different Therapeutic Product.
IPSCIO Record ID: 240614
Licensor owns and controls certain patent rights relating to methods and compositions in the field of antibodies.
Licensed Patent is for Methods of producing immunoglobulins, vectors and transformed host cells for use therein.
Licensed Product shall mean any antibody that binds specifically to CD40, the making or having made, using, selling, offering for sale or importing of which, but for the license granted under this Agreement, would infringe a Valid Claim of a patent included in Licensed Patents.
CD40 is an integral membrane protein found on the surface of B lymphocytes, dendritic cells, follicular dendritic cells, hematopoietic progenitor cells, epithelial cells, and carcinomas. It is a 45-50 kDa glycoprotein of 277 aa, which is a member of the tumor necrosis factor receptor superfamily.
IPSCIO Record ID: 299303
Licensor Patent Rights means the inventions patentable under applicable patent law that are claimed in the patent applications and patents listed (a) hereto and all divisions, continuations, continuations-in-part, applications claiming priority thereto, and substitutions thereof; all foreign patent applications corresponding to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any patents or patent applications, whether now existing or obtained in the future, owned or controlled by Licensor containing a claim that is dominating over the foregoing patent rights (i.e., is necessarily infringed by the practicing of a claim in one of the foregoing applications); and any patents or patent applications covered by any Licensor Third Party Licenses, a list of which is set forth.
6,171,820 – Saturation mutagenesis in directed evolution
6,479,258 – Non-stochastic generation of genetic vaccines
Licensor Evolution Technologies means the inventions patentable under applicable patent law that are claimed in the Licensor Patent Rights which both (a) are owned or controlled by Licensor and (b) either (i) comprise evolution of a gene and/or gene pathway by changing more than 50% of the codons and/or amino acids of such gene and/or genepathway to more than 50% of every other possible codon and/or amino acid or such gene and/or gene pathway, or (ii) comprise evolution of a gene and/or gene pathway by creating and screening a non-stochastically produced library of molecules by combining tragments of a plurality of genes chosen by design to reassemble compleete genes and/or gene pathways according to the patentable methods embodied by inventions described in the Licensor Patent Rights.
Licensed Immunoglobulin means (a) with respect to the licenses and rights granted, any Immunoglobulin discovered, isolated or characterized by Licensor through the use of Antibody Evolution, and (b) with respect to the licenses granted, Licensed Immunoglobulin includes any Immunoglobulin discovered using Antibody Evaluation but outside the Manufacturing Field, and for purposes of this agreement hereof, Licensed Immunoglobulin includes any Immunoglobulin within the Manufacturing Field.
Licensed Immunoglobulin Information means any data, know-how or other information relating, concerning or pertaining to a Licensed Immunoglobulin, including without limitation data, know-how or other information characterizing or constituting such Licensed Immunoglobulins polynucleotide or amino acid sequence, purported function or utility, antigen binding affinity, or physical or biochemical property.
Immunoglobulin means any molecule, including without limitation, full immunoglobulin molecules (e.g., IgG, IgM, IgE, IgA and IgD molecules) and ScFv, Fv and Fab molecules, that has an amino acid sequence by virtue of which it specifically interacts with an antigen and wherein that amino acid sequence consists essentially of a functionally operating region of an antibody variable region including without limitation any naturally occurring or recombinant form of such a molecule.
Licensee Patent Rights means the inventions patentable under applicable patent law that are claimed in the patent applications and patents listed hereto and all divisions, continuations, continuations-in-part, applications claiming priority thereto, and substitutions thereof; all foreign patent applications corresponding to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any patents or patent applications, whether now existing or obtained in the future, owned or controlled by Licensee containing a claim that is dominating over the foregoing patent rights (i.e., is necessarily infringed by the practicing of a claim in one of the foregoing applications).
5,595,898 – Modular assembly of antibody genes, antibodies prepared thereby and use
6,204,023 – Modular assembly of antibody genes, antibodies prepared thereby and use
Licensee Technology Platform means all know-how, trade secrets, inventions, data, processes, procedures, devices, methods, formulas, media and all cell lines, reagents, protocols and other information, whether or not patentable, that either (a) constitute or relate to any biological target, antigen, receptor, cell, expression vector, disease, condition, nucleic acid, protein (including, without limitation, an Immunoglobulin) or protein-conjugate which is the subject of or arises out of any Licensee Project or (b) relate to the discovery, optimization, expression or manufacture of Immunoglobulins, in each case which are owned by or licensed to Licensee as of the Effective Date and are disclosed to Licensor or used by Licensor or Licensee in connection with a Licensee Project. For the avoidance of doubt, the term 'Licensee Platform Technology' shall include any prokaryotic expression technology and methods and/or antibody phage display technology and methods.
Licensor Collaborator means any person or entity on whose behalf Licensor engages in Antibody Evolution and/or a person or entity who is the intended recipient of Licensed Immunoglobulins or Licensed Immunoglobulin Information transferred from Licensor.
Licensee Development Product means any composition of matter or article of manufacture consisting essentially of an Immunoglobulin or protein discovered or optimized by Licensor for Licensee pursuant to a Licensor Action Plan and where such Immunoglobulin or protein was discovered or optimized using techniques, methods or materials covered by one or more Valid Claims of any patent or patent application controlled by Licensor, including the Licensor Patent Rights.
Licensor Field means (a) Research and Development and (b) the diagnosis, treatment, prevention or prophylaxis of any human or animal condition or disease. The Licensor Field shall not include any Non-Approved Uses.
Manufacturing Field means the production in prokaryotes of an Immunoglobulin for the treatment, diagnosis or prophylaxis of a human or animal disease or condition in quantities which exceed Research Quantities, and shall include commercial, industrial or clinical scale production.
